Tags

Type your tag names separated by a space and hit enter

Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
Urol Int. 2017; 98(4):466-471.UI

Abstract

AIM

There is a large body of evidence of clinical studies regarding the relation between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men. A possible link between inflammation and these 2 clinical entities has also been proposed. Here, we aimed at evaluating the role of neutrophil-lymphocyte ratio (NLR), an indicator of inflammation and MetS, in the pathogenesis of LUTS and other BPH-related parameters.

METHOD

We evaluated 244 patients with benign prostate hyperplasia admitted to our outpatient clinic between January 2014 and June 2015. NLR was calculated from the peripheral blood sample for all patients. Patients' anthropometric characteristics, serum lipid levels, waist circumferences, total prostate-specific antigen (PSA) and testosterone values, prostate volumes, max values and International Prostate Symptom Score (IPSS) were recorded. All statistical analyses were conducted by SPSS version 17.0 package program, and p value <0.05 was chosen as the criterion for statistical significance.

RESULTS

There was statistical significance between NLR and patients with severe IPSS score (>20) and over age 60 years (p = 0.02). Patients younger than 60 years had statistical significance between NLR and PSA <2.5 ng/dl (p = 0.004). When body mass index was selected, there was statistical significance between prostate volume <35 ml (p = 0.009) and age >60 years (p = 0.028). If 60 years of age was selected as cut-off value, there is statistical significance between age and severe IPSS, and in terms of mild erectile dysfunction, PSA >2.5 ng/dl, and prostate volume >35 ml.

CONCLUSION

We found positive correlation between NLR and severe symptoms and progression of BPH. In this manner, anti-inflammatory therapy could contribute to the medical treatment of BPH. Higher NLR may be a candidate marker for severity of symptoms in BPH patients.

Authors+Show Affiliations

Department of Urology, Izmir Ataturk Training and Research Hospital, Izmir, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27464069

Citation

Ozer, Kutan, et al. "Association Between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome." Urologia Internationalis, vol. 98, no. 4, 2017, pp. 466-471.
Ozer K, Horsanali MO, Gorgel SN, et al. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urol Int. 2017;98(4):466-471.
Ozer, K., Horsanali, M. O., Gorgel, S. N., Horsanali, B. O., & Ozbek, E. (2017). Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urologia Internationalis, 98(4), 466-471. https://doi.org/10.1159/000448289
Ozer K, et al. Association Between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. Urol Int. 2017;98(4):466-471. PubMed PMID: 27464069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome. AU - Ozer,Kutan, AU - Horsanali,Mustafa Ozan, AU - Gorgel,Sacit Nuri, AU - Horsanali,Burcu Ozalp, AU - Ozbek,Emin, Y1 - 2016/07/28/ PY - 2016/04/25/received PY - 2016/07/10/accepted PY - 2016/7/28/pubmed PY - 2018/4/17/medline PY - 2016/7/28/entrez KW - Benign prostate hyperplasia KW - Lower urinary tract symptoms KW - Metabolic syndrome KW - Neutrophil-lymphocyte ratio SP - 466 EP - 471 JF - Urologia internationalis JO - Urol Int VL - 98 IS - 4 N2 - AIM: There is a large body of evidence of clinical studies regarding the relation between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men. A possible link between inflammation and these 2 clinical entities has also been proposed. Here, we aimed at evaluating the role of neutrophil-lymphocyte ratio (NLR), an indicator of inflammation and MetS, in the pathogenesis of LUTS and other BPH-related parameters. METHOD: We evaluated 244 patients with benign prostate hyperplasia admitted to our outpatient clinic between January 2014 and June 2015. NLR was calculated from the peripheral blood sample for all patients. Patients' anthropometric characteristics, serum lipid levels, waist circumferences, total prostate-specific antigen (PSA) and testosterone values, prostate volumes, max values and International Prostate Symptom Score (IPSS) were recorded. All statistical analyses were conducted by SPSS version 17.0 package program, and p value <0.05 was chosen as the criterion for statistical significance. RESULTS: There was statistical significance between NLR and patients with severe IPSS score (>20) and over age 60 years (p = 0.02). Patients younger than 60 years had statistical significance between NLR and PSA <2.5 ng/dl (p = 0.004). When body mass index was selected, there was statistical significance between prostate volume <35 ml (p = 0.009) and age >60 years (p = 0.028). If 60 years of age was selected as cut-off value, there is statistical significance between age and severe IPSS, and in terms of mild erectile dysfunction, PSA >2.5 ng/dl, and prostate volume >35 ml. CONCLUSION: We found positive correlation between NLR and severe symptoms and progression of BPH. In this manner, anti-inflammatory therapy could contribute to the medical treatment of BPH. Higher NLR may be a candidate marker for severity of symptoms in BPH patients. SN - 1423-0399 UR - https://www.unboundmedicine.com/medline/citation/27464069/Association_between_Benign_Prostatic_Hyperplasia_and_Neutrophil_Lymphocyte_Ratio_an_Indicator_of_Inflammation_and_Metabolic_Syndrome_ L2 - https://www.karger.com?DOI=10.1159/000448289 DB - PRIME DP - Unbound Medicine ER -